Syndax Pharmaceuticals, a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies, today announced that the Company granted inducement awards to purchase up to 78,700 shares of common stock to four new employees under the Company's 2023 Inducement Plan.

The stock options will vest over four years, with 25% of the underlying shares vesting on the one-year anniversary of the vesting commencement date and 1/48th of the underlying shares vesting monthly thereafter over 36 months, subject to the employee's continued service relationship with Syndax through the applicable vesting dates.

A pharmaceutical company is defined as a company that invests in researching, producing, and marketing drugs/medicines for the treatment of diseases, relying on medical data and reports of patients for drug discovery.

Syndax Pharmaceuticals is a commercial-stage biopharmaceutical company developing an innovative pipeline of cancer therapies. Highlights of the Company's pipeline include revumenib, a selective menin inhibitor, and Niktimvo™ (axatilimab-csfr), an FDA-approved monoclonal antibody that blocks the colony stimulating factor 1 (CSF-1) receptor.

Syndax Pharmaceuticals is a biopharmaceutical company that develops cancer therapies. At Syndax, we are determined to realize a future in which people with cancer live longer and better than ever before. We believe that it takes a community to build a great medicine, and that is why we are working to set the new standard for developing medicines in the field of oncology one that revolves around collaboration, shared learning, and excellence.

Syndax’s mission is to obtain regulatory approval and commercialize drugs that extend and improve the lives of cancer patients by drawing on the newest scientific research and advances, collaborating with determined problem solvers, and identifying value in overlooked aspects of science.

Fueled by our commitment to reimagining cancer care, Syndax is working to unlock the full potential of its pipeline and is conducting several clinical trials across the continuum of treatment. For more information, please visit www.syndax.com or follow the Company on X (formerly Twitter) and LinkedIn.

 

Source: prnewswire.com

Report Abuse